Monte Rosa Therapeutics (GLUE) Non-Current Assets (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Non-Current Assets of $58.9 million for Q1 2026, down 3.35% year-over-year from $60.9 million in Q1 2025, and up 6.14% quarter-over-quarter from $55.5 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Non-Current Assets (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $58.9 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 3.35% year-over-year to $58.9 million; the TTM figure through Mar 2026 stood at $232.5 million (down 7.85% YoY), while the FY2025 annual figure was $55.5 million, down 9.49% from the prior year.
- Non-Current Assets for Q1 2026 stood at $58.9 million, up from $55.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $70.5 million in Q2 2023, with the low at $25.6 million in Q1 2022.
- The 5-year median for Non-Current Assets is $63.9 million (2024), against an average of $61.8 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 538.48% in 2022, then slipped 10.03% in 2025.
- Monte Rosa Therapeutics' Non-Current Assets stood at $66.5 million in 2022, then rose by 1.56% to $67.5 million in 2023, then slipped by 9.25% to $61.3 million in 2024, then fell by 9.49% to $55.5 million in 2025, then gained by 6.14% to $58.9 million in 2026.
- Business Quant data shows GLUE's Non-Current Assets at $58.9 million in Q1 2026, $55.5 million in Q4 2025, and $58.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 59.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.76 Mn |
| Mar 31, 2026 | 58.88 Mn |
| Dec 31, 2025 | 55.47 Mn |
| Sep 30, 2025 | 58.02 Mn |
| Jun 30, 2025 | 60.12 Mn |
| Mar 31, 2025 | 60.92 Mn |
| Dec 31, 2024 | 61.29 Mn |
| Sep 30, 2024 | 63.87 Mn |
| Jun 30, 2024 | 66.22 Mn |
| Mar 31, 2024 | 67.71 Mn |
| Dec 31, 2023 | 67.54 Mn |
| Sep 30, 2023 | 69.19 Mn |
| Jun 30, 2023 | 70.51 Mn |
| Mar 31, 2023 | 68.47 Mn |
| Dec 31, 2022 | 66.50 Mn |
| Sep 30, 2022 | 62.37 Mn |
| Jun 30, 2022 | 68.01 Mn |
| Mar 31, 2022 | 25.64 Mn |
| Dec 31, 2021 | 17.66 Mn |
| Sep 30, 2021 | 13.53 Mn |